NetworkNewsAudio – 180 Life Sciences Corp. Dedicated to Developing Groundbreaking Anti-Inflammatory Drugs

Related Editorial
Inflammation typically occurs in the body as a natural response to threats such as infection or injury, but chronic inflammation can cause severe damage and even death. Inflammation is a well-known symptom of multiple infectious diseases. However, multidiscipline research strongly suggests that inflammation is also closely linked with a broad range of noninfectious diseases. The critical aspects of the interplay between inflammation and disease may well be the key to development of a new generation of drugs to treat previously untreatable diseases, sparking a flurry of biotech research and development in the field. At the vanguard of this new drug development, 180 Life Sciences Corp. (NASDAQ: KBLM) (180 Profile) is driving groundbreaking studies in clinical programs aimed at developing novel therapeutics that address distinct areas of inflammation, finally offering hope for vast unmet medical needs in inflammatory diseases, fibrosis, pain and more. Amgen Inc. (NASDAQ: AMGN) acquired the anti-inflammatory drug Enbrel for $4.8 billion in 2018 and, in conjunction with AbbVie Inc. (NYSE: ABBV) and others, is testing anti-inflammatory drugs in a joint COVID-19 study. Actemra, an anti-inflammatory arthritis drug from Roche Holding Ltd. (OTCQX: RHHBY) previously failed to meet its primary endpoint in earlier COVID trials. Johnson & Johnson (NYSE: JNJ) now owns Remicade, which was developed by the current management of 180 Life Sciences, the first tumor necrosis factor-α (TNF) inhibitor and one of the top anti-inflammatory drugs in the world with over $5 billion in sales in 2019 alone.

To hear the AudioPressRelease, visit

To view the full editorial, visit

About 180 Life Sciences Corp.

180 Life Sciences is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. KBL Merger Corp. IV (NASDAQ: KBLM) previously announced plans to merge with 180 Life Sciences and, in connection with the merger, consummated a bridge financing on June 29, 2020, and submitted its latest S4 filing with the SEC on August 28, 2020. Close of the business combination is expected in the fourth quarter of 2020. Following the merger, the new company will be listed on the Nasdaq Capital Market under ticker symbol “ATNF.” For more information, visit the company’s website at

KBLM has valued 180 Life Sciences at $175 million, with the acquisition being carried out via a share swap, with each share of 180 Life Sciences to be exchanged for one share of KBLM.

NOTE TO INVESTORS: The latest news and updates relating to 180 Life Sciences are available in the company’s newsroom at

About NetworkNewsAudio

NetworkNewsAudio, a service of NetworkNewsWire (NNW), allows you to sit back and listen to market updates, interviews and company press releases. NetworkNewsAudio keeps you informed on publicly traded companies we’re watching. The audio clips provide snapshots of position, opportunity and momentum. NetworkNewsAudio is a Brand Awareness Distribution Solution from NetworkNewsWire.

For more information, visit

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published:

NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office

NetworkNewsWire is part of the InvestorBrandNetwork.

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.